Price Chart

Profile

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. The company lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes.
URL https://www.vtvtherapeutics.com
Investor Relations URL https://ir.vtvtherapeutics.com/
HQ State/Province North Carolina
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 06, 2024 (est.)
Last Earnings Release Nov. 09, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. The company lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes.
URL https://www.vtvtherapeutics.com
Investor Relations URL https://ir.vtvtherapeutics.com/
HQ State/Province North Carolina
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 06, 2024 (est.)
Last Earnings Release Nov. 09, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A